USFDA approved

Marinol

This is a locally preserved regulatory record. Source labeling does not by itself prove efficacy for a condition.

Regulatory product record. The connected regulator reports this product as approved, authorised or currently marketed.

Product data

Locally preserved regulatory fields

Active ingredients: DRONABINOL, marinol
Route: ORAL
Dosage form: CAPSULE
Marketing holder: ThePharmaNetwork, LLC
Catalog status: FDA approved
Source-reported status: FDA approved

Medicine name group

3 preserved variants

Records share the same exact normalized name. Different identifiers, strengths, countries, presentations and statuses remain separate.

FDA approvedUSCurrent record

Marinol

Strength not reported

ORAL · CAPSULE

50 identifiers · DailyMed structured labels · Drugs@FDA application data · FDA drug labels (openFDA) · FDA Orange Book

Cancelled Post MarketCA

MARINOL

DRONABINOL · 5 MG

Oral · Capsule

3 identifiers · Health Canada Drug Product Database

Cancelled Post MarketCA

MARINOL

DRONABINOL · 2.5 MG

Oral · Capsule

3 identifiers · Health Canada Drug Product Database

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Cannabinoids and active compounds

Delta(9)-tetrahydrocannabinol

Condition reports

Chronic Pain Multiple Sclerosis Alzheimer Disease Cancer Pain Stress Disorders, Post-Traumatic Opioid-Related Disorders Bipolar Disorder

Regulatory record

Approval, patents and exclusivity

Patent and exclusivity fields are preserved from the regulator. They are not a legal opinion and are separate from clinical development.

12approval records

0source-reported patents

0exclusivity records

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · Not reported

U.S. FDA

FDA approved

Approval / market date · 2020-02-07

U.S. FDA

FDA approved

Approval / market date · 2020-02-07

U.S. FDA

FDA approved

Approval / market date · 2020-02-07

U.S. FDA

FDA approved

Approval / market date · 1985-05-31

U.S. FDA

FDA approved

Approval / market date · 1985-05-31

U.S. FDA

FDA approved

Approval / market date · 1985-05-31

Clinical development

Related registered studies

Phases and statuses are source-reported study stages matched by governed token phrases. They do not prove medicine identity, approval or efficacy.

152candidate study links

PHASE2

Source-reported use

Indications in regulatory records

1 INDICATIONS & USAGE MARINOL is indicated in adults for the treatment of: • anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). • nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. MARINOL is a cannabinoid indicated in adults for the treatment of: • Anorexia associated with weight loss in patients with AIDS. (1) • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

1 INDICATIONS AND USAGE Dronabinol capsules are indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol capsules are a cannabinoid indicated in adults for the treatment of: Anorexia associated with weight loss in patients with AIDS. (1) Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. (1)

1 INDICATIONS AND USAGE Dronabinol capsules are indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol capsules is a cannabinoid indicated in adults for the treatment of: Anorexia associated with weight loss in patients with AIDS. ( 1 ) Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )

Medicine identity matching